Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

Related Keywords

United States ,America ,Campbellp Semaglutide Wegovy ,Mikhail Kosiborod ,European Society Of Cardiology ,Novo Nordisk ,Luke Mid America Heart Institute Mikhail Kosiborod ,Research For Saint Luke Health System ,Luke Mid America Heart Institute ,Mid America Heart Institute ,European Society ,Saint Luke ,Drug Administration ,Once Weekly ,Obesity Related Heart Failure ,Preserved Ejection Fraction ,South America ,Kansas City Cardiomyopathy Questionnaire ,New England Journal ,Semaglutide 2 4 Mg ,Wegovy ,Hfpef ,Heart Failure ,Esc Congress 2023 ,